Looked at Q3 filing on Sedar again Burn rate for ACT is mentioned as $15M over 6 years, with possibility of big upside due to many factors.
Said FDA submissions will be based on assessment of 25 patients @450 day, in Q4 '22 (subject to blah blah...). If this was delayed beyond Q1'23 and they didn't even mention it to shareholders till now, they will probably lose all trust and will struggle to raise money. So I'm thinking the BTD application is in and we're in wait mode.
My BEST GUESS from the financial statements is that they need ~$1.25M to $1.5M per quarter to operate (with most of it going to ACT) , even after revenues from the laser division. They had ~$2.5 M in working capital left end of Q3'22. So who knows, maybe they're close to running on fumes. Insiders bought nearly $700K worth of shares (2.9 M) in Q3-Q4. So I don't expect any more funding from there, unless RDW's aunt Martha wants to invest her pension in her favorite nephew's company.
So it feels like all roads lead to them giving it their best shot with the FDA , most ikely in Q1. Hoping the FDA approves. If they ask for more data or delay it for whatever reason, it'll be a sad day indeed.